ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2023, 'International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology', Kidney International, 104, pp. 36 - 45, http://dx.doi.org/10.1016/j.kint.2023.03.007
,2023, 'Introducing the International Home Dialysis Consortium', Kidney International Reports, 8, pp. 1277 - 1280, http://dx.doi.org/10.1016/j.ekir.2023.04.019
,2023, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial', American Journal of Kidney Diseases, 82, pp. 84 - 96.e1, http://dx.doi.org/10.1053/j.ajkd.2022.12.015
,2023, 'Our shared responsibility: the urgent necessity of global environmentally sustainable kidney care', Kidney International, 104, pp. 12 - 15, http://dx.doi.org/10.1016/j.kint.2022.12.015
,2023, 'Skilled Health Workforce Emigration: Its Consequences, Ethics, and Potential Solutions', Mayo Clinic Proceedings, 98, pp. 960 - 965, http://dx.doi.org/10.1016/j.mayocp.2023.02.035
,2023, '#3676 EVALUATION OF HAEMOGLOBIN RESPONSE IN PATIENTS WITH CKD-RELATED ANAEMIA NOT ON DIALYSIS RECEIVING DAPRODUSTAT OR CONTROL IN ASCEND-ND', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063a_3676
,2023, '#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063a_3848
,2023, 'Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working group', Kidney International, 103, pp. 1028 - 1037, http://dx.doi.org/10.1016/j.kint.2023.02.033
,2023, 'Innovative mobile-health led participatory approach to comprehensive screening and treatment of diabetes (IMPACT diabetes): rationale, design, and baseline characteristics', International Journal of Diabetes in Developing Countries, 43, pp. 353 - 362, http://dx.doi.org/10.1007/s13410-022-01082-3
,2023, 'Perspectives on early detection of chronic kidney disease: the facts, the questions, and a proposed framework for 2023 and beyond', Kidney International, 103, pp. 1004 - 1008, http://dx.doi.org/10.1016/j.kint.2023.03.009
,2023, 'The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease', Kidney International, 103, pp. 1180 - 1192, http://dx.doi.org/10.1016/j.kint.2023.02.019
,2023, 'Climate Change, Heat-Related Acute Kidney Disease, and the Need for Action', American Journal of Kidney Diseases, 81, pp. 501 - 503, http://dx.doi.org/10.1053/j.ajkd.2022.11.002
,2023, 'Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)', American Journal of Nephrology, 54, pp. 1 - 13, http://dx.doi.org/10.1159/000528696
,2023, 'Wisdom of the Crowd: insights gained from comparing predicted and observed effects of blood pressure lowering strategies', Journal of Human Hypertension, 37, pp. 422 - 424, http://dx.doi.org/10.1038/s41371-023-00816-y
,2023, 'Personalized Treatment of PLA2R-Related Membranous Nephropathy', Clinical journal of the American Society of Nephrology : CJASN, 18, pp. 530 - 532, http://dx.doi.org/10.2215/CJN.0000000000000086
,2023, 'Urinary exosomal miRNA-663a shows variable expression in diabetic kidney disease patients with or without proteinuria', Scientific reports, 13, pp. 4516, http://dx.doi.org/10.1038/s41598-022-26558-4
,2023, 'Complementary medicine and phospholipase A2 receptor (PLA2R)–related membranous nephropathy—fortuitous or causal?', Kidney International, 103, pp. 425 - 427, http://dx.doi.org/10.1016/j.kint.2022.11.008
,2023, 'Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial', Acta Anaesthesiologica Scandinavica, 67, pp. 195 - 205, http://dx.doi.org/10.1111/aas.14167
,2023, 'National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas', PLOS Global Public Health, 3, http://dx.doi.org/10.1371/journal.pgph.0001467
,2023, 'A Mobile Clinical Decision Support System for High-Risk Pregnant Women in Rural India (SMARThealth Pregnancy): Pilot Cluster Randomized Controlled Trial', JMIR Formative Research, 7, http://dx.doi.org/10.2196/44362
,2023, 'Challenges and opportunities in interventions for chronic kidney disease of unknown origin (CKDu): report from the International Society of Nephrology Consortium of Collaborators on CKDu', Kidney International, 103, pp. 6 - 12, http://dx.doi.org/10.1016/j.kint.2022.10.013
,2023, 'Developing Standard Treatment Workflows—way to universal healthcare in India', Frontiers in Public Health, 11, http://dx.doi.org/10.3389/fpubh.2023.1178160
,2023, 'Effect of Vitamin D Supplementation on Serum Hepcidin Levels in Non‑Diabetic Chronic Kidney Disease Patients', Indian Journal of Nephrology, 33, pp. 444 - 448, http://dx.doi.org/10.4103/ijn.ijn_28_23
,2023, 'Indian TrANslational GlomerulonephrItis BioLogy nEtwork (I.TANGIBLE): Design and Methods', Indian Journal of Nephrology, 33, pp. 277 - 282, http://dx.doi.org/10.4103/ijn.ijn_305_23
,2023, 'Renal Revolution: Anticipating the Next 25 Years of India's Kidney Care', Indian Journal of Nephrology, 33, http://dx.doi.org/10.4103/ijn.ijn_125_23
,2023, 'Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis', Journal of Medical Economics, 26, pp. 1407 - 1416, http://dx.doi.org/10.1080/13696998.2023.2264715
,2023, 'Trends in the Global Burden of Glomerulonephritis', Clinical journal of the American Society of Nephrology : CJASN, 18, pp. 14 - 16, http://dx.doi.org/10.2215/CJN.0000000000000029
,2023, 'A Randomized Trial of Nafamostat for Covid-19.', NEJM Evid, 2, pp. EVIDoa2300132, http://dx.doi.org/10.1056/EVIDoa2300132
,2023, 'Association of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) with the Progression of CKD in Indian CKD Cohort', Journal of the American Society of Nephrology, 34, pp. 389 - 389, http://dx.doi.org/10.1681/asn.20233411s1389a
,2023, 'Atacicept 150 mg Reduces Serum Gd-IgA1, a Biomarker Associated with Long-Term Outcomes in IgA Nephropathy (IgAN): 36W Results from the Ph2b ORIGIN Study', Journal of the American Society of Nephrology, 34, pp. 974 - 975, http://dx.doi.org/10.1681/asn.20233411s1974c
,2023, 'Effect of Cholecalciferol Supplementation on Immune Modulation, Inflammation, and Vascular Function in CKD', Journal of the American Society of Nephrology, 34, pp. 676 - 676, http://dx.doi.org/10.1681/asn.20233411s1676a
,2023, 'Hemoglobin Stability in the ASCEND-TD Trial', Journal of the American Society of Nephrology, 34, pp. 75 - 76, http://dx.doi.org/10.1681/asn.20233411s175d
,2023, 'Intact Fibroblast Growth Factor 23 and Progression of CKD', Journal of the American Society of Nephrology, 34, pp. 389 - 389, http://dx.doi.org/10.1681/asn.20233411s1389b
,2023, 'Patterns of multimorbidity among a community-based cohort in rural India.', J Multimorb Comorb, 13, pp. 26335565221149623, http://dx.doi.org/10.1177/26335565221149623
,2023, 'Transparent reporting of adaptive clinical trials using concurrently randomised cohorts.', BMJ Med, 2, pp. e000497, http://dx.doi.org/10.1136/bmjmed-2023-000497
,2023, 'WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL', Kidney International Reports, 8, pp. S51 - S52, http://dx.doi.org/10.1016/j.ekir.2023.02.118
,2023, 'WCN23-0146 CHOLECALCIFEROL SUPPLEMENTATION IN CHRONIC KIDNEY DISEASE: EFFECT ON IMMUNE AND VASCULAR FUNCTION', Kidney International Reports, 8, pp. S232 - S232, http://dx.doi.org/10.1016/j.ekir.2023.02.521
,2023, 'WCN23-0200 PREVALENCE AND TREATMENT PATTERNS OF ANAEMIA IN INDIVIDUALS WITH CHRONIC KIDNEY DISEASE ACROSS ASIA', Kidney International Reports, 8, pp. S135 - S136, http://dx.doi.org/10.1016/j.ekir.2023.02.309
,2023, 'WCN23-0576 SOLUBLE UROKINASE RECEPTOR (suPAR) LEVELS AND INCIDENT CHRONIC KIDNEY DISEASE IN STOP-CKDu COHORT', Kidney International Reports, 8, pp. S173 - S174, http://dx.doi.org/10.1016/j.ekir.2023.02.390
,2023, 'WCN23-0776 BARRIERS TO ACCESSING ESSENTIAL MEDICINES IN NEPHROLOGY AND RELATED NON-COMMUNICABLE DISEASES: A SCOPING REVIEW', Kidney International Reports, 8, pp. S239 - S239, http://dx.doi.org/10.1016/j.ekir.2023.02.539
,2023, 'WCN23-0955 Performance of latest eGFR equations in Indian population', Kidney International Reports, 8, pp. S124 - S125, http://dx.doi.org/10.1016/j.ekir.2023.02.282
,2023, 'WCN23-0960 ASSESSMENT OF CAUSES OF DEATH IN A POPULATION REPRESENTATIVE COHORT AT RISK OF CHRONIC KIDNEY DISEASE OF UNKNOWN ORIGIN, USING SmartVA TECHNOLOGY', Kidney International Reports, 8, pp. S179 - S180, http://dx.doi.org/10.1016/j.ekir.2023.02.400
,2023, 'WCN23-0985 INCIDENTAL DISCOVERY AND EXTRACTION OF MIGRATED GUIDEWIRE FROM RIGHT FEMORAL VEIN CATHETERIZATION: A CASE REPORT', Kidney International Reports, 8, pp. S334 - S335, http://dx.doi.org/10.1016/j.ekir.2023.02.747
,2023, 'WCN23-1128 Allopurinol for CVD in CKD (AvoiD-CKD): Baseline characteristics from a double blind, randomized controlled trial', Kidney International Reports, 8, pp. S160 - S160, http://dx.doi.org/10.1016/j.ekir.2023.02.361
,2022, 'Renin-angiotensin blocker use is associated with improved cardiovascular mortality in Indian patients with mild-moderate chronic kidney disease—findings from the ICKD study', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1060148
,2022, 'ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial', Trials, 23, http://dx.doi.org/10.1186/s13063-022-06929-y
,2022, 'Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial', Trials, 23, pp. 361, http://dx.doi.org/10.1186/s13063-022-06167-2
,2022, 'Epidemiology of peritoneal dialysis outcomes', Nature Reviews Nephrology, 18, pp. 779 - 793, http://dx.doi.org/10.1038/s41581-022-00623-7
,2022, 'Peritoneal catheter insertion: combating barriers through policy change', Clinical Kidney Journal, 15, pp. 2177 - 2185, http://dx.doi.org/10.1093/ckj/sfac136
,2022, 'Serum myo-inositol oxygenase levels at hospital discharge predict progression to chronic kidney disease in community-acquired acute kidney injury', Scientific Reports, 12, http://dx.doi.org/10.1038/s41598-022-17599-w
,